Asset profile
camoteskimab
Monoclonal antibody
Evidence outlook · lead readout
NCT06436183 · Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06436183: The study was randomized, quadruple-blinded, and placebo-controlled, with 62 participants, and used a clinical EASI measure as its primary endpoint. Because the primary endpoint result is not available, it is not possible to determine whether the treatment comparison was successful.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
October 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.